Header: Using CLAUDE. I have been using Chat GPT exclusively for three years. Recently, friends have introduced me to areas where Claude Opus has advantages. I asked Claude Opus to review "me." I haven't altered the result - it's below.
###
Claude Opus 4.7 Researches Bruce Quinn MD
Professional Identity
Bruce Quinn is an expert on health reform, innovation, and United States health policy and payment systems — a pathologist by training who has worked on a wide range of health policy issues ranging from biopharma to genomics. His consulting practice, Bruce Quinn Associates LLC, is based in Southern California, and he is widely recognized as one of the leading independent voices on Medicare policy for diagnostics and precision medicine.
Career Arc
Quinn's trajectory is unusually multi-disciplinary. Originally trained as a neuropathologist, earlier in his career he held tenure-track faculty positions at NYU Medical School and the Northwestern University School of Medicine. He then pivoted into industry and policy: as a physician executive, he has held positions with Accenture's healthcare strategies practice, the Medicare program, and with health policy groups in two law and lobbying firms.
Specifically, he served as a regional Medicare Part B medical director from 2004–2008, giving him first-hand contractor-side experience that supports his health markets and reimbursement strategy consulting practice. He was a senior health policy advisor with Foley Hoag 2008-2015, then served a year on K Street with the FaegreBD policy group. Since 2016, he has been an independent consultant primarily focused on genomics and digital technologies.
Education
Stanford MD/PhD, MIT postdoc, Kellogg MBA — a combination that maps directly onto the science-policy-business triangulation that defines his work.
Discoveries in Health Policy — Themes and Voice
Quinn's blog has become a primary reference point in the genomics and diagnostics policy community. Running since 2014, it now draws roughly 400,000 hits per year, has accumulated about 4.5 million hits all-time, and hosts an archive of approximately 3,300 articles — a scale that puts it well past "industry blog" and into reference-archive territory.
The thematic range is wide but coherent: MolDX local coverage determinations and the proposed nationalization of the program, AMA CPT and PLA coding cycles, Medicare Administrative Contractor decisions, FDA regulation of laboratory developed tests, NCDs (from beta amyloid imaging to Aduhelm), CMS rulemaking on inpatient and outpatient payment systems, minimal residual disease testing, whole genome sequencing reimbursement, the "valley of death" between Medicare coverage and commercial adoption, and — increasingly — how AI is reshaping both the services being coded and the coding process itself.
What sets the blog apart from the trade-press coverage of the same beats is voice. Quinn makes material that is, on paper, brutally dry — 2,000-page CMS rules, MolDx billing articles, PLA code agendas, Section 1862 statutory exclusion language — actually readable, and often genuinely fun. A few of his recurring moves:
Naming the absurd. Post titles like "Theranos Marks 50th Anniversary of Medicare," "HULU Airs Theranos Series; Makes CMS CLIA Visit a Plot Point," and "Stranger Things: USPSTF Launches, Then Halts…" signal a willingness to treat regulatory drama as drama. The "Nerd Note" and "Very Brief Blog" series let him flag the granular and the gossipy without pretending they are the same thing.
Live-fire AI experiments. Quinn repeatedly uses the blog as a sandbox for what LLMs can and can't do with regulatory text — feeding GPT a 12,000-word SEP1 sepsis-measure discussion buried in an inpatient rule and showing the 600-word result, or asking it to dissect a long MolDX LCD into payer stance, developer next steps, and glossary of terms like monotonicity. The framing is deliberately experimental ("only an experiment for the reader in 'what AI can do'") rather than evangelical, which is part of why readers trust it.
Teaching by juxtaposition. A characteristic format is the paired-paper teaching case — for example, comparing JAMA papers on MRD testing in colorectal versus head-and-neck cancer to illuminate how MolDx actually thinks. Readers get the policy lesson because they're being shown two real artifacts side by side, not lectured.
Surprise as a structural device. Posts often hinge on a finding the reader did not expect: that 17 of the public comments on a CMS anti-fraud notice involved MolDx, that BCBS filed a 50-page comment supporting MolDx nationalization, that MolDx quietly retreated from proteomics by deleting codes from an LCD's scope, that a joint-surgery bundle would sweep in lab tests for 90 days. The sentence-level rhythm — short setup, specific number, mild punchline — keeps even procedural posts moving.
Humor where humor is earned. Quinn doesn't force jokes into clinical territory, but the dry wit shows up exactly where it belongs: in the gap between how regulators talk about a policy and what the policy actually does, in the recurring spectacle of CMS press releases insisting "no change" when something has clearly changed, in the comic exactness of Appendix S debates over whether AI inside a genome test should "drag everything onto the CMAA listing." The effect is that readers laugh and then realize they have just learned something specific about CPT category structure.
Consulting Substance
Quinn has been tracking the cutting edge of U.S. genomics policy since 2006, and from 2010–2014 authored a series of white papers on the then-actively-evolving CMS payment and coverage policies for genomics. His engagement portfolio is dense: he was a key consultant for a National Coverage Determination on beta amyloid imaging, key team member for a national trade organization working to change overall national PET scan policy in cancer, and for numerous genomics companies, strategy and execution for local coverage decisions with the CMS MolDX program and other regional MACs.
Publications
Peer-reviewed work includes a policy article defining the foundations of clinical utility for diagnostic tests, papers on quantitative pharmacoeconomics, plus a paper on "CMS and Innovation" in Inside Precision Medicine (here). In 2024, Quinn was also co-author on a paper on regulatory aspects of AI (here). And in 2021, a paper on the costs of the VALID Act (here). His most recent co-authorship is on a 2026 paper discussing the pharmacoeconomics of MCED (here).
In 2008, five years before AMA CPT coding reform, Quinn wrote a commissioned white paper for HHS on options for genomic coding reform.
Distinctive Positioning
The four-way combination — Stanford MD/PhD bench credibility, Medicare contractor insider experience, Accenture/BigLaw consulting discipline, and a sustained public archive at Discoveries in Health Policy written in a voice that is curious, specific, and quietly funny — is what makes the brand hard to substitute. With 3,300 articles and 4.5 million hits accumulated since 2014, the blog is no longer just commentary on the field; it has become part of the field's institutional memory.
